Account
Former Pfizer Inc. (PFE) Chairman and Chief Executive Jeff Kindler has joined venture-capital firm Lux Capital, to help work with the firm's portfolio companies and identify new health-care investment opportunities."With tremendous leadership experience in the health-care industry, Jeff has an appreciation for the intersection of novel science, product development and commercial transactions," said Robert Paull, managing partner at Lux Capital.Mr. Kindler joined Pfizer as an executive vice president and general counsel in 2002 and was promoted to chairman in 2006. He left the pharmaceutical company in December 2010, citing fatigue, although investors also had grown anxious as a result of the stock's 36% decline under his leadership.New York-based Lux Capital is an early investor in energy, technology, health-care and life sciences companies, funding developments from rapid vaccine discovery to nano-enabled drug delivery. Its investments include biopharmaceutical company Cerulean Pharma...
National Legal & Policy Center President Pete Flaherty on the political dimensions behind Jeff Kindler stepping down as CEO of Pfizer.
FOX Business: The Power to ProsperAfter bouncing between minor gains and losses throughout the day, Wall Street landed on the fence on Monday, preserving virtually a...
FOX Business: The Power to ProsperStock futures pointed to modest declines early Monday as U.S. traders, armed with little economic data or company news of their own...
FBN's Sandra Smith on Pfizer CEO Jeff Kindler announcing his retirement after four and a half years.
Pfizer 's President and CEO Jeffrey Kindler unexpectedly resigned his post, the company said in a statement late Sunday, ending his 4-1/2 year tenure as head of the ...
Helped by its $67 billion mega merger with Wyeth, Pfizer (NYSE:PFE) reported second-quarter results on Tuesday that solidly beat Wall Street’s expectations and issue...
Pfizer and Wyeth CEOs
Jeff Kindler talks about pharmaceuticals
September 23, 2008 05:31 PM UTC by Liz ClamanPFIZER CHAIRMAN AND CEO TO FBN: PASS THE BAILOUT PLAN NOWGang,Jeff Kindler, Chairman and CEO of Pfizer (PFE) joined me e...
Pfizer Inc (NYSE:PFE) said Chief Executive Ian Read's compensation jumped more than 40 percent last year to $25 million as he steered a steady course for the world's...
DAVOS , Switzerland, Jan 24 (Reuters) - Corporate executives are struggling to find paths to growth as the euro zone crisis stokes fears of a return to recession and...
By Lewis KrauskopfNEW YORK (Reuters) - Pfizer Inc <PFE.N> may have won over shareholders with its recent decision to pare back research and development spending but ...
By Ransdell PiersonNEW YORK (Reuters) - Pfizer Inc is expected to report slightly lower quarterly earnings on Tuesday, but investors will be more focused on any sign...
GOP members of the powerful U.S. House Energy and Commerce Committee have stepped up their probe of secret back-room negotiations and quid pro quo deals struck in he...
To fill a new void at the top of the Commerce Department , the White House is reportedly thinking about tapping Google (NASDAQ:GOOG) CEO Eric Schmidt or former Pfize...
FBN's Connell McShane on the compensation package Pfizer CEO Jeff Kindler will receive.
Quotes delayed at least 15 minutes. Real-time quotes provided by BATS Exchange. Market Data provided by Interactive Data (Terms & Conditions). Powered and Implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund and ETF data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.
This material may not be published, broadcast, rewritten, or redistributed. ©2013 FOX News Network, LLC. All rights reserved.